7:00 AM GMT, Aug 1, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact firstname.lastname@example.org.
Tykerb: Completed Phase III enrollment
GlaxoSmithKline completed enrollment in the open-label, Asian Phase III TyTAN trial comparing Tykerb plus
Read the full 147 word article